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Abstract
Background: Maternal Embryonic Leucine Zipper Kinase (MELK) is a serine/threonine kinase involved in cell cycle,
differentiation, proliferation, and apoptosis. These multiple features are consistent with it being a potential
anticancer target. Nevertheless, the MELK pathway in tumorigenesis is not yet completely understood. This study
aims to identify proteins associated with MELK pathway in astrocytomas. To this end, proteomic data of the human
glioma cell line U87MG transfected with siRNA for MELK were compared with non-target transfected control cells
and compared with oligonucleotide microarray data.
Results: In both assays, we identified stathmin/oncoprotein 18 (STMN1), involved in cell cycle. STMN1 gene
expression was further assessed in a series of 154 astrocytomas and 22 non-neoplastic brain samples by qRT-PCR.
STMN1 expression was significantly increased in malignant diffusely infiltrative astrocytomas compared with
pilocytic astrocytoma (p < 0.0001). A strong correlation between MELK and STMN1 expressions was observed
(r = 0.741, p < 0.0001) in glioblastoma (GBM) samples. However, no difference on survival times was found when
compared GBM cases with upregulated and downregulated STMN1 (Breslow = 0.092, median survival time: 11 and
13 months, respectively). Functional assays knocking down MELK by siRNA in GBM cell line showed that gene and
protein expression of both MELK and stathmin were diminished. On the other hand, when the same analysis was
performed for STMN1, only stathmin gene and protein was silenced.
Conclusions: The results presented herein point stahtmin as a downstream target in the MELK pathway that plays
a role in malignant progression of astrocytomas.
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Background
Eighty percent of primary central nervous system malig-
nant tumours are gliomas, and astrocytomas constitute
more than half of gliomas [1]. According to the 2007
World Health Organization (WHO), these tumours are
classified into four grades: grade I or pilocytic astrocyto-
mas (AGI), grade II or diffuse astrocytomas (AGII),
grade III or anaplastic astrocytomas (AGIII) and grade
IV (AGIV) or glioblastomas (GBM) [2]. GBM accounts
for the majority of astrocytomas and can be further
divided into two subgroups: primary GBM, which arises
de novo, and secondary GBM, which results from the
progression of a lower grade astrocytoma. Astrocytomas
ranging from AGII to GBM are considered as diffusely
infiltrating astrocytomas and therefore are not curable
via resection due to the invasive malignant tumour cells
in the surrounding normal brain tissue [2–5].
Furthermore, the therapeutic outcome of conventional
treatments remains unsatisfactory [5, 6], and the overall
5-year survival rate of GBM remains less than 5 % and is
even lower for elderly patients [7]. The identification of
additional therapeutic targets remains a challenge for
GBM treatment. In addition, novel molecules that are
specifically mutated or overexpressed in cancer cells
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provide both mechanistic insight regarding tumour es-
tablishment and progression as well as potential targets
for the development of new anticancer drugs. In this
context, serine/threonine kinases represent an extensively
examined protein class, and targeting these molecules in a
specific manner has proven not only to be very effective
but also to minimize unfavourable side effects [8].
In a previous report, our group has demonstrated a
stepwise expression level increase of the serine/
threonine kinase Maternal Embryonic Leucine Zipper
Kinase (MELK) in parallel with the increasing degree of
malignancy in astrocytomas [9]. Additionally, the rele-
vance of MELK in other brain tumours, including me-
dulloblastomas, meningiomas, and oligodendrogliomas,
has been described [9, 10], along with many other solid
tumour types, such as colorectal, lung, ovary [11], breast
[12] and prostate tumours [13]. Moreover, MELK has
been shown to be associated with poor prognosis in
breast and prostate cancer patients [12, 13].
MELK is also known as murine protein serine/threo-
nine kinase 38 (MPK38) [14] and Eg3 protein (pEg3)
[15]. MELK is a cell cycle-dependent protein kinase that
belongs to the KIN1/PAR-1/MARK family of serine-
threonine kinases [15–17]. It is localised in the cyto-
plasm and nucleus during interphase and at the cell
cortex during anaphase and telophase [18]. MELK,
activated via autophosphorylation, phosphorylates sev-
eral substrates which modulates intracellular signalling
in several cellular and biological processes. Further-
more, MELK interacts by binding to the following mol-
ecules: a) cell cycle protein (CDC25B), inducing cell
accumulation in G2 [16], b) zinc finger-like protein 9
(ZPR9), a physiological substrate of MELK kinase in
vivo [19], c) mitosis-promoting factor (MPF) and
mitogen-activated protein kinase (MAPK), enhancing
kinase activity [20], d) members of the Bcl-2 family of
proapoptotic genes (Bcl-GL), conferring resistance to
apoptosis [21, 22], e) inhibitor of protein Ser/Thr
phosphatase-1 (NIPP1), transcription and splicing fac-
tor, regulating cell cycle progression through pre-mRNA
processing [23],f ) PDK1, an enzyme responsible for Akt/
PKB loop activation, inhibiting its activity and function, g)
Smad proteins, Smad2, Smad3, Smad4, and Smad7, intra-
cellular signalling mediators of the TGF-β signalling
pathway, regulating their activity [24], and h) p53, tumour
suppressor, enhancing p53-dependent apoptosis and
arresting cycle cell by modulating p53 stability [25].
MELK is also involved in embryonic development
[19, 26] and is enriched in multiple multipotent
neural progenitor-containing populations. MELK in-
duces expression of POU5F1, a well-known stem cell
marker, particularly in hematopoietic stem cells [27, 28].
MELK has been considered a potential target for can-
cer therapy because of the interaction with multiple
proteins at distinct stages of tumorigenesis [29, 30], and
the first MELK-specific small molecular compound,
OTSSP167, was developed [29]. However, the down-
stream signalling pathway of MELK in cancer cells is still
not fully understood, and the putative function of MELK
in astrocytomas remains unclear. The discovery of genes
and/or proteins involved in the MELK pathway might
contribute to the development of additional compounds
to improve treatment effectiveness.
In the present study, we performed a comparative
proteomic analysis and used oligonucleotide microarrays
to analyze the differential pattern of expression before and
after knocking down MELK to investigate the proteins
and genes involved in the signalling pathways. Addition-
ally, we have selected one MELK-associated protein to
further investigate its function in astrocytoma progression.
The protein stathmin and its coding gene (STMN1)
presented lower expression whenMELK was silenced.
Results
Stathmin is one of the proteins identified as down-
regulated when MELK is knocked down
A proteomic study based in 2DE was performed to
analyze proteome changes in U87MG cells in which
MELK was knocked down. The transfection reduced
efficiently MELK expression at gene and protein levels.
Twelve differentially expressed proteins (Table 1) were
identified via 2D gel image analysis (Fig. 1a) and mass
spectrometry. The differentially abundant proteins are
shown in Fig. 1b, considering the % volume of the spot
to be equivalent to the expression level (n = 3, mean ±
SD, p < 0.05). Five proteins displayed up-regulation after
MELK silencing: tripeptidyl-peptidase 1 (TPP1), prote-
asome activator complex subunit 2 (PSME2), lamin-A/C
(LMNA), complement component 1 Q subcomponent-
binding protein, mitochondrial (C1QBP) and annexin
A2 (ANXA2). On the other hand, seven proteins
presented down-regulation when MELK was knocked
down: gamma-enolase (ENOG), aldose reductase (ALDR),
T-complex protein 1 subunit gamma (TCPG), stathmin
(STMN1), superoxide dismutase [Cu-Zn] (SODC), ATP
synthase subunit d, mitochondrial (ATP5H) and stress-
induced-phosphoprotein 1 (STIP1) as shown in Table 1,
Fig. 1b, Additional file 1: Table S1.
STMN1 was confirmed as down-regulated after knocking
down MELK
Following the selection criteria regarding data mining,
gene annotation and in silico validation from an initial
44,000 genes analyzed on the oligonucleotide microarray
assays, we found 667 overrepresented common genes
with a fold change (NTC/MELK) ≥ 2 in two independent
experiments. After gene annotation based on a public
database, we found 87 overrepresented genes via
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hypergeometric test (p < 0.05) and 26 genes functionally
associated with tumorigenesis. Subsequently, we checked
the expression of these genes in silico based on our pre-
vious microarray data [9]. Five genes out of 26 were se-
lected as down-regulated in astrocytomas, preferentially
in higher malignant grades and tumour-related func-
tions. These genes were metallopeptidase domain 9
(ADAM9), EPH receptor B4 (EPHB4), lectin, galactoside-
binding soluble 12 (LGALS12), WNT1 inducible signalling
pathway protein 1 (WISP1) and stathmin (STMN1) as
shown in Additional file 2: Figure S2, Additional file 3:
Table S3 and Additional file 4: Figure S4).
Interestingly, STMN1 was the common target that was
down-regulated together with MELK as detected by
proteomic and microarray analyzes. Therefore, STMN1
expression was further analyzed simultaneously with
MELK gene expression in a series of astrocytomas of
different malignant grades and non-neoplastic (NN)
brain tissues.
MELK and STMN1 expression levels are higher in the most
malignant astrocytomas
We analyzed MELK and STMN1 expression levels in
the series of tissue samples, which included control
NN and astrocytoma of all malignant grades. MELK
expression levels were higher in GBM samples (median
value = 0.28, SD ± 1.04) compared with lower grades as-
trocytomas. Of note, the majority of NN tissues (17 out
of 22) displayed that MELK expression was below the
detection level of the method (Fig. 2a). A significant
difference in STMN1 expression levels was also ob-
served among the groups (p < 0.0001), and diffusely in-
filtrative astrocytomas (AGII to IV) presented higher
expression levels than non-invasive pilocytic astrocyto-
mas (AGI) (p < 0.0005, p < 0.0005 and p < 0.05, respect-
ively). Furthermore, STMN1 expression levels were
higher in NN brain tissue than in AGI samples (p <
0.00005) (Fig. 2b).
Moreover, MELK expression levels significantly corre-
lated with STMN1 expression levels in GBM samples
(Fig. 3a). The correlation in gene expression also increased
with the incremental increase in malignancy grade, as the
association was non-significant in AGI (r =−0.008, p =
0.971), while it was slight in AGII (r = 0.330, p = 0.100),
moderate in AGIII (r = 0.426, p = 0.088), and strong in
GBM (r = 0.741, p < 0.0001) (Fig. 3a). These results of
co-expression were confirmed in TCGA Research
Network data of a GBM data set (r = 0.52 and 0.62,
Person and Spearman correlation, respectively) as
shown in Fig. 3b. Altogether, these findings support the
hypothesis that MELK and STMN1 may act in the same
pathway, mainly in GBM.




Acc UniProt Protein identification Protein fold change MELK/







1 ANXA2_HUMAN Annexin A2 3.49 ± 0.08 1003 38832/
7.57
13 41.6
2 TCPG_HUMAN T-complex protein 1 subunit
gamma
0.55 ± 0.06 395 61104/6.1 9 19.4
3 PSME2_HUMAN Proteasome activator complex
subunit 2





0.52 ± 0.02 325 63266/6.4 6 13.8
5 ENOG_HUMAN Gamma-enolase 0.51 ± 0.09 246 47610/
4.91
4 11.1
6 ALDR_HUMAN Aldose reductase 0.50 ± 0.04 101 36252/
6.51
3 11.4
7 ATP5H_HUMAN ATP synthase subunit d,
mitochondrial
0.44 ± 0.02 152 18548/
5.21
4 24.2
8 STMN1_HUMAN Stathmin 0.52 ± 0.01 145 17302/
5.76
2 16.8
9 C1QBP_HUMAN Complement component 1 Q
subcomponent-binding protein,
mitochondrial
1.86 ± 0.06 141 31761/
4.74
2 9.9
10 TPP1_HUMAN Tripeptidyl-peptidase 1 2.21 ± 0.04 139 61761/
6.01
4 10.7
11 SODC_HUMAN Superoxide dismutase [Cu-Zn] 0.42 ± 0.06 104 16164/5.7 1 9.1
12 LMNA_HUMAN Lamin-A/C 2.08 ± 0.09 83 74424/
6.57
4 6
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Fig. 1 (See legend on next page.)
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MELK and STMN1 expression levels impact on overall
survival of GBM patients
GBM cases were divided into increased expression and
decreased expression status of MELK and STMN1 ac-
cording to their expression transcript levels.
However, no difference on survival times was found
when compared GBM cases with upregulated and
downregulated STMN1 (Breslow = 0.092, median survival
time at 11 and 13 months, respectively) and for MELK
(log rank: 0.745)
MELK and stathmin proteins are expressed in
astrocytomas
MELK and stathmin were both in the cytosolic
localization. MELK and stathmin expressions were
detected in in different levels of NN brain cells. Neverthe-
less, stathmin expression levels were higher than MELK
expression levels in NN tissues (the cells with morpho-
logical characteristics of neurons) (Fig. 4a and g). Both
MELK and stathmin expressions in astrocytoma were
higher in more malignant astrocytomas (Fig. 4b–e and
Fig. 4h–k, respectively), as represented in the semi-
quantitative analysis (4 F and 4 L, respectively).
Stathmin is downstream in the MELK pathway
Expression of MELK and STMN1 was knocked out by
specific siRNA transfection of U87MG glioma cell line.
The gene and protein expression levels of both targets
were checked in both conditions in two independent
experiments. When MELK was efficiently silenced (95
and 70 % compared to NTC), STMN1 expression was
also considerably diminished to 70 % (Fig. 5a). In
contrast, when STMN1 was knocked out (99 and 98 %
relative to NTC), no change in MELK expression was
detected (Fig. 5b). Altogether, these data confirmed that
stathmin is downstream MELK pathway.
Discussion
In our previous study, we have also demonstrated that
MELK knockdown in malignant astrocytoma cell lines
caused a reduction in proliferation and anchorage-
independent growth in in vitro assays [9]. The present
study reveals stathmin as a novel target involved in the
MELK pathway, based on both proteomic and gene
expression approaches, using the strategy of MELK
knock down with siRNA. We have previously shown a
significant correlation between MELK expression and as-
trocytoma malignant grade, with the highest expression
levels in GBM samples [9]. Herein, we observed that
MELK expression also correlated with STMN1 expres-
sion levels in GBM samples, both in our series and
TCGA GBM samples.
Stathmin was the common target detected in both
proteomic and oligonucleotide microarray analyzes, when
comparing protein and gene profiles before and after
MELK silencing. Furthermore, this target was selected in
the present study because of its involvement in many im-
portant features of different types of tumors as invasion
and metastasis, proliferation, survival, tumor grade and
prognosis. Stathmin is a cytosolic phosphoprotein initially
identified in neuroendocrine cells of the pituitary under
conditions of stimulation with thyreotropin-releasing hor-
mone (TRH) [31]. Stathmin regulates microtubule dynam-
ics during cell cycle progression [32]. Non-phosphorylated
or active stathmin promotes depolymerisation of microtu-
bules by sequestering tubulin, while phosphorylated or in-
active stathmin increases microtubule stabilisation and
promotes mitotic spindle formation [33]. Although cells
proceed through anaphase and telophase, fluctuations in
microtubule polymerisation and depolymerisation lead
to structural reorganisation and eventual spindle disas-
sembly, followed by exit from mitosis and cytokinesis.
Microtubules then reorganise into a new interphase
cytoskeleton upon entry into a new cell cycle [34].
We detected higher STMN1 expression levels in diffusely
infiltrative astrocytomas (AGII to AGIV) compared with
AGI. Furthermore, STMN1 expression levels were higher
in NN brain tissue than in AGI samples. This is in con-
cordance with the previously demonstrated function of
stathmin in cell proliferation, as its level increases during
the S and G2/M phases and decreases when cells accumu-
late in the G1 phase [35]. Stathmin also plays a role in
neoangiogenesis, as high grade glioma-derived microvascu-
lar endothelial cells treated with STMN1 siRNA reduce cell
viability, increase apoptosis rates and suppress significantly
the endothelial cell migration [35]. Moreover, stathmin
phosphorylation at serine 16 mediates the ‘pioneering’ of
microtubules into the leading edge of migrating cells,
(See figure on previous page.)
Fig. 1 Proteomics analysis of differentially expressed proteins in U87MG transfected with siRNA for MELK compared with U87MG transfected with
non-target control. a Representative two-dimensional electrophoresis gels (2DE). Protein extracts (200 μg) were applied to 2DE using IPG pH 3-
10NL (7 cm) for isoelectric focusing and 12.5 % SDS-PAGE mini gels as a second dimension. Gel image analysis was performed using ImageMaster
2D Platinum v.7.0 software. The arrows indicate selected protein spots from mass spectrometry analysis. b Proteins differentially expressed
(up-regulated and downregulated) in the glioma cell line U87MG transfected with siRNA for MELK compared with U87MG cells transfected with
non-target control (NTC). The expression levels of 12 differentially expressed protein spots were quantified on the basis of the normalised
volume of the 2DE spots (% vol) for each group. These data were analysed via ANOVA (p < 0.05). The data are reported as the mean ± SD.
One of the proteins, Stathmin (STMN1), exhibited lower expression levels when MELK was silenced
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Fig. 2 Gene expression levels in astrocytomas of different malignant grades (AGI, AGII, AGIII and GBM) and non-neoplastic brain tissues (NN). Expression
levels of MELK a and STMN1 (b) were analyzed by quantitative real-time PCR (qRT-PCR) using the SYBR Green method. The following equation was
applied to calculate gene expression levels: 2-ΔCt, in which ΔCt = Ct of the target gene-geometric mean Ct of reference genes. Horizontal bars
indicate the median relative expression levels of all tissues. The differences in MELK and STMN1 expression levels among the groups were
statistically significant (Kruskal-Wallis test, p < 0.0001). MELK expression levels were higher in GBM samples (median value = 0.28) than the other
groups. STMN1 median expression levels for NN, AGI, AGII, AGIII and AGIV were 21.7, 5.7, 16.9, 21.8 and 12.2, respectively. A post-hoc Dunn’s
test was used to calculate the differences in expression between NN and each astrocytoma group (**** p < 0.00005, *** p < 0.0005, ** p < 0.005
and * p < 0.05). The results are presented in log10 scale for better visualisation
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Fig. 3 Correlation between MELK and STMN1 gene expression levels in glioblastomas. qRT-PCR data analysis in our series of 86 cases a RNAseq
data analysis in 154 cases TCGA was analyzed for co-expression of MELK and STMN1 by z-Score (of RSEM) [54, 55] (b)
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acting downstream Rac1 and Pak pathways [36]. Stathmin
has been previously reported to act as a substrate of several
intracellular signalling kinases, as mitogen-activated protein
kinases (MAPKs) and phosphoinoinositide 3-kinase (PI3K)
and phosphorylation at serine residues is the main
mechanism of regulation of its activity [37]. Stathmin
Fig. 4 MELK and stathmin protein expression in non-neoplastic and astrocytoma tissue samples. Immunohistochemistry was performed for MELK
a–f and stathmin (g–l) in 6 cases each of in (a and g) non-neoplastic (NN) brain tissues, (b and h) pilocytic (AGI), (c and i) low grade (AGII), (d and j)
anaplastic (AGIII) astrocytomas, and (e and k) glioblastoma (GBM). Pictures show representative cases of each sample type, with 400-x magnification.
The bar (k) represent the scale bar of 10 μm. The graphs (f and l) represent a semi-quantitative immunolabelling score (ILS) calculated as the product
of staining intensity and the percentage of positive cells. Both MELK and stathmin showed positive staining in the cytosol. MELK reactivity increased
with the increment of the malignancy among diffusely infiltrating astrocytomas (AGII-AGIV). Stathmin cytosol staining was stronger in GBM cases. The
horizontal bars show the median ILS of each group
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can be dephosphorylated by protein phosphatise 1
(PP1), protein phosphatase 2A (PP2A)and protein
phosphatase 2B (PP2B) [38–40].
Therefore, stathmin plays a major role in tumour pro-
gression and dissemination rather than tumour initiation
as suggested, independent of the histology of the pri-
mary tumour. The reduced expression of STMN1 in
AGI samples compared with NN brain tissue and a step-
wise increase that parallels the incremental increase in
malignant grade in higher grades of invasive astrocyto-
mas, as shown in the present study, corroborate this
suggestion.
The associated expression of MELK and STMN1 dem-
onstrated in GBM cases on this study and TCGA public
data may be explained by two pathways, via p53 or
FOXM1. FOXM1 is a master transcription factor that
regulates mitotic progression of different types of cancer
cells and forms a protein complex with MELK in glioma
stem-like cells, leading to phosphorylation and activation
of FOXM1 in a MELK kinase-dependent manner [41].
FOXM1 induces STMN1 expression in B-cell lymphoma
[42], breast cancer [43] and gastric cancer [44]. On the
other hand, MELK carboxyl-terminal domain can phys-
ically interact with the central DNA-binding domain of
p53, promoting p53 activity through direct phosphoryl-
ation at Ser15. Consequently, activated p53 promotes
apoptosis and cell cycle arrest, as well as transcription of
target genes, including STMN1, which has a promoter
with p53-binding domain [45, 46]. Also, MELK both reg-
ulates and is regulated by one family of MAP kinases,
the c-Jun NH(2)-terminal kinases (JNKs) in a cancer-
specific manner [47]. The tumor-specific MELK inter-
action with the JNK/c-JUN is likely one of the mecha-
nisms for the selective apoptosis that occurs as a result
of MELK inhibition in GBM stem cells, but not in nor-
mal progenitors. These cells give rise to a variety of
tumor cells in response to cellular and environmental
signals, and may play a role in tumor initiation and
propagation [48]. A proposal of the signaling pathway of
MELK that highlights stathmin activation via FOXM1
and p53 is presented in Fig. 6, where a disturbance on
the pathway involving MELK and stathmin may lead to
alterations of tumor cell cycle progression, proliferation,
and migration.
A MELK-specific small molecule compound, named
OTSSP167, displayed significant suppression of phos-
phorylation levels of PSMA1 (proteasome subunit alpha
type 1) and DBNL (drebrin-like). Both of these targets
were identified as novel MELK substrates, and they
proved to be important for stem cell characteristics and
invasiveness. This compound suppresses mammosphere
formation in breast cancer cells and has exhibited sig-
nificant tumour growth suppression in xenograft stud-
ies using breast, lung, prostate, and pancreatic cancer
cell lines in mice via both intravenous and oral admin-
istration [8]. Actually, MELK seems to be a druggable
target as MELK overexpression has also been associated
with poor prognosis in breast and prostate cancer [12,
13]. Nevertheless, in the present series of astrocytomas,
no correlation was observed between GBM patient
survival outcome and MELK and STMN1 expression
status. In contrast, STMN1 overexpression has been
Fig. 5 Effect of MELK and STMN1 knockdown with siRNA in GBM cell line. MELK and STMN1 expression levels relative to non-targeting control (NTC)
were analyzed two days after transfection of U87MG cell line a The data show the average of two independent experiments and the vertical bar
represents the standard deviations. Western blot of MELK and stathmin were analyzed after trasfection with siRNA for both genes and NTC (b)
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associated with poor survival as well as with local or
distant metastasis formation in several types of human
cancer, including bladder, breast, cervical, colorectal,
gastric, head and neck, hepatocellular, ovarian, prostate
and urothelial carcinomas [37]. Therefore, these evi-
dences suggest that combined targeting of MELK and
stathmin might yield a better result. However, the high
expression levels of stathmin in normal brain may be
an impediment to its eligibility as a therapeutic target
for brain tumours. Therefore, further search for other
druggable targets downstream stathmin and MELK
might help to establish other therapeutic strategies.
Conclusions
The results presented herein point stathmin as a down-
stream target in the MELK pathway that plays a role in
malignant progression of astrocytomas. The effective
role of these downstream targets on the MELK-stathmin
network in the cell cycle process may be explored in
future studies. In addition, more detailed mechanisms
with upstream and downstream signaling MELK path-
ways still need to be identified.
Methods
Cell culture and transient transfection with siRNA
The human malignant astrocytoma cell line U87MG was
obtained from the American Type Culture Collection
(Manassas, VA, USA), and the cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10 % fetal calf serum (FCS), 100 IU/ml
penicillin and 100 μg/ml streptomycin in a humidified
incubator at 37 °C with a controlled 5 % CO2 atm.
A total of 1x105 U87MG cells were seeded in a six-
well plate and transfected after 24 h with MELK
siRNA (GUAUAAAGCCAUUACAUUAUCAUCAUC)
and STMN1 siRNA (UACUAAGUGCUGUCCACUAA
UAUGCAC) (27mers double-stranded RNA dicer-
substrate, IDT, Coralville, IA) and cells were also
Fig. 6 MELK and stathmin signaling. MELK can induce stathmin expression through two transcription factors, p53 and FOXM1. A tyrosine kinase
receptor (TKR) is activated by phosphorylation after binding to a ligant. Growth factor receptor-bound protein 2 (GRB2) binds to the phophorylated
residue of TKR and to Son of Sevenless homologs (SOS). GRB/SOS complex activates phosphoinositide 3-kinase (PI3K) and RAS-MAPK signaling
pathways. Activation of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathways results in phosphorylation
of stathmin on serine sites and consequent microtubule stability and cell cycle progression. Stathmin may be dephosphorylated by protein
phosphatase 1 (PP1), protein phosphatase 2A (PP2A) and protein phosphatase 2B (PP2B), resulting in microtubule instability. TKR: tyrosine
kinase receptor; P: phosphorylation
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transfected with using Lipofectamine RNAiMAX (Life
Technologies, Carlsbad, CA). Control cells were trans-
fected with scrambled non-targeting control (NTC)
siRNA (IDT). siRNA concentrations for MELK and
STMN1 were 10 nM and 0.1nM, respectively. MELK and
STMN1 knocking down was assessed using quantitative
real time PCR (qRT-PCR) and Western blot after 48 h of
transfection. For functional analysis of MELK and STMN1
knockdown after siRNA transfection, the HPRT was used
as a reference gene. The expression values were calculated
relative to the control NTC.
Experiments were performed in duplicates (gene ex-
pression analysis) and triplicates (proteomic analysis).
We analysed if MELK is upstream or downstream of
STMN1 in the pathway, then we tested the expression of
MELK and STMN1 using qRT-PCR and Western blot-
ting in two conditions: before and after U87MG cell line
was transfected (1x105 cells) with: a) 10nM siRNA-
MELK and 10nM siRNA-NTC and b) 0.1nM-siRNA-
STMN1 and 0.1nM siRNA-NTC
Proteomics
Protein extraction
Cell pellets of siRNA-NTC and siRNA-MELK U87MG
cells were resuspended in lysis solution with 7.7 M urea,
2.2 M thiourea, 4 % CHAPS and a protease inhibitor
cocktail (Sigma Aldrich, St. Louis, MO). The cell pellets
were then placed in an ultrasound bath (UltraSonic Clear
750, UNIQUE) for three cycles of 5 min for complete pel-
let resuspension and subsequently centrifuged at 20,000xg
for 30 min at 4 °C. Protein concentration was determined
using the Bradford protein assay method.
2DE and image analysis
For the first dimension, Immobiline Dry IPG strips
(7 cm, pH 3–10 non-linear; GE Healthcare, Uppsala,
Sweden) were re-hydrated for 12 h with 200 μg of each
sample, 0.5 % IPG buffer 3–10 non-linear, 0.3 % DTT
and electrophoresis lysis buffer until reaching the final
volume of 125 μL. The isoelectric focusing was per-
formed in an IPGphor system (Ettan IPGphor III, GE
Healthcare) at 20 °C with a constant current of 50 mA
per IPG strip until an accumulation of 40,000 Vh was
reached. After isoelectric focusing, the IPG strips were
reduced with DTT and alkylated with iodoacetamide,
and SDS-PAGE 12.5 % was then performed as the sec-
ond dimension. The proteins were stained with colloidal
Coomassie blue. The gel images were acquired with a
transmissive scanner (ImageScanner, Pharmacia-Biotech,
GE Healthcare) using MagicScan software (GE Health-
care) and analyzed with Image-Master 2D Platinum v.7.0
software (GE Healthcare). The spot volume was measure
and reported as percent volume of the spot (normalized
volume of spots, % vol) in relation to the sum of all
detected spot and this provided normalized spot vol-
umes. Differential protein abundance was detected on
the basis of relative % vol. Reproducibility was deter-
mined by the number of matched spots in relation to
the reference group (control). Differential protein levels
were detected on the basis of a relative % volume ratio
for each group, and the protein spots were accepted as
differentially expressed when p < 0.05 (ANOVA).
Trypsin digestion and mass spectrometry analysis
Selected protein spots were manually excised from the gels.
SDS and Coomassie blue were removed by successive
washes of 50 % acetonitrile in 0.1 M of ammonium bicar-
bonate pH 7.8, followed by dehydration in neat acetonitrile
and drying in a Speed Vac (Savant, New York, NY). Pro-
teins were then digested with 0.5 μg modified trypsin (Pro-
mega Corp., Madison, WI) in 0.1 M ammonium
bicarbonate for 18 h at 37 °C. The reaction was stopped by
adding 1 μL of neat formic acid. Tryptic peptides were ex-
tracted via passive elution and desalted in micro-tips filled
with reverse phase resin (POROS R2, Perseptive Biosys-
tems, Foster City, CA), which were previously equilibrated
in 0.2 % formic acid. Samples were de-salted via two washes
of 0.2 % formic acid (150 μL). Peptides were eluted in
30 μL of a 60 % methanol/5 % formic acid solution, con-
centrated in Speed Vac and resuspended in an α-cyano-4-
hidroxicinamic acid matrix solution (5 mg/mL). Two to five
microliters of each sample was loaded into the MALDI tar-
get and analyzed via MALDI-TOF-TOF mass spectrometer
(Axima Performance—Kratos-Shimadzu, Manchester, UK).
Two to five microliters of each sample was loaded into
the MALDI target and analyzed by MALDI-TOFTOF mass
spectrometer (Axima Performance—Kratos-Shimadzu,
Manchester, UK). MALDI-TOF/TOF was calibrated with a
synthetic peptide mixture of Bradykinin fragment 1–7
(757.40); Angiotensin II (1046.54); P14R (1533.85) and
ACTH fragment 18–39 (2465.20) (Sigma-Aldrich, Saint
Louis, CA) in CHCA matrix. Mass spectra resolution were
FWHM of 10,000 and accuracy <50 ppm which were
collected for MS using 10 shots/profile with 64 pro-
files/spectrum at laser power of 90. CID-MS/MS spec-
tra were selected as data dependent acquisition (DDA)
for the 10th most abundant ions in MS spectra using
20 keV and helium as collision gas. Laser power was set-
ting to 110 and 10 shots/profile with 256 profiles/
spectrum. Mass spectra peak list was generated by Launch-
pad v. 2.8.2 software (Kratos-Shimadzu, Manchester, UK)
as mascot generic format and only CID-MS/MS spectra
were used for protein identification using home-licensed
MASCOT server software (v 2.4.04).
Protein identification
PMF and CID-MS/MS spectra from 2 DE selected pro-
tein spots were submitted for protein identification by
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searching against the Swiss-Prot database version 57.2
and filtered for Homo sapiens (total of 20,402 human se-
quences) using MASCOT version 2.2.04. The database
search parameters were set as follows: hydrolysis of tryp-
sin, one missing cleavage was allowed, fixed modification
for carbamidomethyl-Cys and variable modification for
methionine oxidation. The mass tolerance for precursor
ions was 1.2 Da, and the mass tolerance for fragment
ions was set to 0.8 Da. Protein identification was
supported by MS/MS analysis of individual ions by CID-
MS/MS. Proteins were identified on the basis of at least
two unique peptides if the score was higher than 35
(p < 0.05) or the amino acid sequence was consistently
covered by a series of ion fragment b and y types.
Microarray hybridisation and gene expression analysis
Total RNA extraction and cDNA synthesis
The total RNA was extracted from cell lines using RNeasy
Mini Kit (Qiagen, Hilden, Germany). Synthesis of cDNA
was performed via reverse transcription using oligo(dT),
random hexamers, and SuperScriptIII (Life Technologies)
according to the manufacturer’s recommendations.
Microarray hybridisation, gene expression analysis and
Criteria of microarray analysis
Initially we performed a microarray analysis to select genes
involved in MELK pathway. The differential gene expres-
sion profiles in the U87MG cell line transfected with
MELKsiRNA compared with NTC-transfected cells was
analyzed by 44 K DNA microarrrays (Whole Human
Genome Microarray Kit, Agilent Technologies, Santa Clara,
CA).
The human U87MG glioma cell lines transfected
(1x105 cells) with oligonucleotide MELK siRNA reduced
MELK expression levels by 95 and 96 % in first and sec-
ond independent experiments, respectively, at the 48 h
confirmed by qRT-PCR and western blotting.
Hybridisation was performed according to the protocol
provided by the manufacturer (One-Color Microarray-
Based Gene Expression Analysis—Quick Amp Labeling,
Agilent Technologies). The images were captured by the
reader Agilent Bundle according to the parameters recom-
mended for bioarrays and extracted using Agilent Feature
Extraction software version 9.5.3, considering spots with
none or only one flag. The selected transcripts were ana-
lyzed with the R software version 2.11.0 (R Development
Core Team, 2008) and the Lowess test was applied for
array normalisation. We obtained common genes with
reduced expression when MELK was silenced compared
with the control considering a fold change (NTC/
MELK) ≥2 in two independent assays. These genes
were annotated using WebGestalt [49].
Workflow for gene selection process of involved in MELK
pathway
Microarray 1
We considered one or more genes in each group as statisti-
cally significant at p < 0.05 by the hypergeometric test. De-
tailed analyzes of each up-regulation gene were performed
using the Gene database of the National Center for Bio-
technology Information (http://www.ncbi.nlm.nih.gov/
gene) and the SAGE database of the Cancer Genome Anat-
omy Project (http://cgap.nci.nih.gov/Genes/GeneFinder).
Microarray 2
Selected differentially expressed genes were validated in
silico with the astrocytoma microarray data (10 k DNA
CodeLink Bioarrays-Human Uniset I; GE Healthcare,) (4
of pilocytic astrocytomas, 6 of low grade astrocytomas, 3
of GBMs and 2 pools of 3 non-neoplastic brain tissues)
previously published [9]. We refined the selection by
choosing down-regulation genes predominantly in GBM
cases, preferentially in higher malignant grades and
tumour-associated functions. The workflow for selection
process of genes involved in MELK pathway was pre-
sented as Additional file 2: Figure S2).
Tumour samples
One hundred and fifty-two astrocytomas (grades I to IV)
and 22 non-neoplastic (NN) brain anonymized tissues
from epilepsy patients subjected to temporal lobectomy
were obtained during therapeutic surgery from patients
treated by the Neurosurgery Group of the Department
of Neurology at Hospital das Clinicas at the School of
Medicine of the University of São Paulo. The cases were
categorised according to the WHO grading system [2]
by neuropathologist from the Division of Pathological
Anatomy at the same institution. The studied series con-
sisted of 22 AGI (mean age: 19.4 years), 26 AGII (mean
age: 34 years), 18 AGIII (mean age: 35 years), 86 GBM
(mean age: 54 years), and 22 NN brain specimens (mean
age: 38 years), according to demographic data presented
in our previous study [50]. Samples were macrodissected
and immediately snap-frozen in liquid nitrogen upon
surgical removal. Necrotic, cellular debris and non-
neoplastic areas were removed by microdissection from
the frozen block prior to RNA extraction [9, 51]. Writ-
ten informed consent was obtained from all adult pa-
tients in accordance with ethical guidelines, and this
project was approved by the local ethical committee.
This study was approved by the Ethic Committee of
School of Medicine of the University of São Paulo
(Protocol# 0263/07).
Total RNA extraction, reverse transcription and qRT-PCR
The total RNA was extracted from frozen tissues using
an RNeasy Mini Kit (Qiagen). The first strand of cDNA
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was synthesised from 1 μg of total RNA previously
treated with 1 unit of DNase I (FPLC-pure, GE Health-
care) using random hexamers, oligo(dT) primers, RNase
inhibitor, and SuperScript III reverse transcriptase ac-
cording to the manufacturer’s recommendations (Life
Technologies). The resulting cDNA was subsequently
treated with one unit of RNaseH (GE Healthcare), di-
luted with TE buffer, and stored at−20 °C until later use.
The relative expression levels of MELK and STMN1
were analyzed by qRT-PCR using the SYBR Green ap-
proach. Quantitative data were normalised using the
geometric mean of three reference genes suitable for the
analysis: hypoxanthine phosphoribosyltransferase (HPRT),
glucuronidase beta (GUSB) and TATA box-binding pro-
tein (TBP), as previously demonstrated by our group [52].
The primers were synthesised by IDT as follows (5′ to 3′):
MELK F: AAACCCAAGGGTAACAAGGA, MELK R: AC
AGTATGCCCATGCTCCAA, STMN1 F: TGTCGCTTG
TCTTCTATTCACCAT, STMN1 R: CTTTTGACCGAG
GGCTGAGA, The primer concentrations used were
200 nM for HPRT, TBP, and STMN1 and 400 nM for
MELK and GUSB. SYBR Green I amplifications were
conducted on an ABI Prism 7500 sequence detector
(Applied Biosystems, Foster City, CA) with an incuba-
tion for 2 min at 50°, 10 min at 95°, followed by 40 cy-
cles of 15 s at 95° and 1 min at 60 °C. All reactions were
performed in duplicates and the following equations were
applied to calculate gene expression levels: 2−ΔCt, in which
ΔCt = Ct target gene-geometric mean Ct of reference
genes [53]. For cellular gene expression analysis, only
HPRT was used as reference gene, and relative expression
was calculated using NTC as reference sample.
Analysis of TCGA GBM gene expression data set
MELK and STMN1 gene expression levels were ana-
lysed in the cBio Portal for Cancer Genomics database
(http://www.cbioportal.org) [54]. RNAseq data set of
154 cases of GBM [55] was analyzed for co-expression
of MELK and STMN1 by z-Score (of RSEM).
Western blot analysis
After transfection with control siRNA (NTC) and siRNA
specific for MELK and STMN1, total protein lysates were
prepared from cell cultures with RIPA lysis buffer and
protease inhibitor cocktail (Sigma-Aldrich) on ice. The
protein concentration was determined using the Brad-
ford reagent (Bio-Rad Laboratories, Richmond, CA) in
duplicates with a standard curve of bovine serum albu-
mine. The absorbance was measured at 595 nm using a
microplate spectrophotometer (Multiskan Spectrum;
Thermo Labsystems, Helsinki, Finland). Total protein ly-
sates (30 μg) were separated by 12 % SDS polyacryl-
amide gel electrophoresis (TGX Mini Protean, Bio-Rad)
with Tris-glycine running buffer and transferred to a
nitrocellulose membrane using the iBlot dry blotting sys-
tem (Life Technologies). The membrane was blocked
with 5 % skim milk and incubated with primary poly-
clonal rabbit anti-MELK antibody (1:2000, Sigma-
Aldrich) and primary monoclonal rabbit anti-Stathmin
antibody (1:1000, Spring Bioscience, clone SP49, Pleas-
anton, CA). The membrane was also incubated with
mouse monoclonal anti-β-actin (1:5000, clone AC-74,
Sigma-Aldrich) as a protein loading control. The sec-
ondary antibodies used were anti-rabbit (1:2000) and
anti-mouse IgG (1:5000) conjugated to peroxidase
(Sigma-Aldrich). The immune complexes were visual-
ized using enhanced chemiluminescence reagent (West-
ern Lightning Chemiluminescence Reagent Plus, Perkin
Elmer, Waltham, MA) and detected with ImageQuant
LAS4000 (GE Healthcare).
Immunohistochemistry analysis of Astrocytoma samples
We analyzed 20 astrocytoma cases (5 cases of each ma-
lignant grade) and 5 NN brain tissues. Serial 5-μm
paraffin-embedded tissue sections of each case were
deparaffinised, rehydrated and treated with endogenous
peroxidase blocking reagent. After antigen retrieval with
citric acid (10 mM pH 6.0) (Merck, USA) at 122 °C for
3 min using an electric pressure cooker (BioCare Med-
ical, Walnut Creek, CA), sections were incubated with
primary polyclonal rabbit anti-MELK, (1:750, Sigma-
Aldrich) and primary monoclonal rabbit anti-Stathmin
antibody (1:100, Spring Bioscience, clone SP49). The
positive controls were normal testis and breast carcin-
oma samples for MELK and stathmin, respectively. The
reactions were carried out using a commercial kit
(Novolink, Novocastra, New Castle-upon-Tyne, UK) at
room temperature with diaminobenzidine and Harris
hematoxylin for nuclear staining.
MELK and stathmin expression levels were analyzed
according to a semi-quantitative score system with both
the intensity of staining and percentage of cells applied
as follows: for intensity of staining, 0: negative, 1: weak,
2: moderate and 3: strong and for percentage of cells
stained, 0: no cells stained, 1: 10–25 %, 2: 26–50 %, 3:
51–75 % and 4: 76–100 %. A immunolabelling score
(ILS) was obtained by the product of the intensity of
staining and the percentage of stained cells. The immu-
nopreparations were analyzed by two independent inves-
tigators, and simultaneous revision were performed to
obtain the final score in case the concordance was not
achieved. Digital photomicrographs of representative
fields were captured and processed using PICASA 3
(Google, Mountain View, USA).
Statistical analyzes
Statistical normality test was performed using the
Kolmogorov-Smirnov and then non-parametric Kruskal-
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Wallis and post-hoc Dunn’s tests were performed for
analysis of the gene expression levels in all grades of as-
trocytoma and NN samples. Correlation between gene
expression values in different groups of tumours was
assessed using the Spearman-rho correlation tests (non-
parametric test).
MELK and STMN1 expression status was scored ac-
cording to the median relative expression values (2−ΔCt)
of each grade of astrocytoma. For statistical analysis,
scores ≥median values were defined as up-regulation
and scores < median values as down-regulation.
Overall survival (OS) time was calculated as the inter-
val between surgery and day of death in months. The
log-rank test was used for univariate analysis to estimate
differences in survival time compared with gene expres-
sion status (up- or down-regulation) in GBM cases ac-
cording to Kaplan-Meier method; the relapse cases (n =
5) were excluded for this analysis. We considered MELK
and STMN1 gene expression status according to the me-
dian relative expression values of GBM (scores ≥median
values were defined as increased expression and scores
< median values as decreased expression for both genes
MELK and STMN1.The definition of MELK and STMN1
mRNA expression status was scored according to the
median expression values (2−ΔCt) of each grade of astro-
cytoma. A multivariate analysis was performed using the
Cox proportional hazards model. The logistic regression
model included the following parameters: age at diagnosis
and gender. Differences were considered statistically sig-
nificant when p < 0.05. The calculations were performed
using SPSS for Windows, version 15.0 (Chicago, IL).
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